{"log_id": 7144070367066950303, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 2e-05, "average": 0.998196, "min": 0.973548}, "location": {"width": 810, "top": 162, "height": 61, "left": 247}, "words": "并未证实这种联合疗法可以增加临床效果,因此不推荐使用(参见“注意事项”)"}, {"probability": {"variance": 6e-06, "average": 0.997738, "min": 0.993075}, "location": {"width": 313, "top": 210, "height": 44, "left": 245}, "words": "本品和柳氮磺胺吡啶联合治疗"}, {"probability": {"variance": 4e-06, "average": 0.998531, "min": 0.991561}, "location": {"width": 775, "top": 260, "height": 60, "left": 291}, "words": "在临床试验中,接受确定剂量柳氮磺胺吡啶治疗的成年患者合并使用本品"}, {"probability": {"variance": 3e-06, "average": 0.998572, "min": 0.992737}, "location": {"width": 824, "top": 306, "height": 63, "left": 240}, "words": "后,与单用本品和单用磺胺类药物相比,合并用药患者的平均白细胞计数显著下"}, {"probability": {"variance": 2e-06, "average": 0.99882, "min": 0.995352}, "location": {"width": 361, "top": 356, "height": 44, "left": 240}, "words": "降。尚未明确这一发现的临床意义"}, {"probability": {"variance": 2e-06, "average": 0.998215, "min": 0.995727}, "location": {"width": 170, "top": 404, "height": 36, "left": 238}, "words": "无药物相互作用"}, {"probability": {"variance": 0.000266, "average": 0.995153, "min": 0.903353}, "location": {"width": 772, "top": 453, "height": 59, "left": 281}, "words": "临床试验发现,本品与糖皮质激素、水杨酸盐类药物(除柳氮磺胺吡啶外)、"}, {"probability": {"variance": 0.000287, "average": 0.993023, "min": 0.917364}, "location": {"width": 822, "top": 499, "height": 61, "left": 234}, "words": "非甾体抗炎药( NSAIDS)、镇痛药或甲氨蝶呤合并使用时未见药物相互作用。(疫"}, {"probability": {"variance": 0.000187, "average": 0.994947, "min": 0.94973}, "location": {"width": 266, "top": 546, "height": 40, "left": 231}, "words": "苗使用参见“注意事项”)"}, {"probability": {"variance": 0.000425, "average": 0.991989, "min": 0.90361}, "location": {"width": 777, "top": 589, "height": 73, "left": 277}, "words": "未发现与甲氨蝶呤,地高辛或华法林合并用药时出现有临床意义的药代动力"}, {"probability": {"variance": 0, "average": 0.999305, "min": 0.998153}, "location": {"width": 228, "top": 641, "height": 40, "left": 226}, "words": "学药物药物相互作用"}, {"probability": {"variance": 0, "average": 0.998743, "min": 0.997829}, "location": {"width": 131, "top": 689, "height": 32, "left": 233}, "words": "【药物过量】"}, {"probability": {"variance": 2e-06, "average": 0.999022, "min": 0.99497}, "location": {"width": 407, "top": 738, "height": 46, "left": 271}, "words": "在类风湿关节炎患者中进行的临床试验"}, {"probability": {"variance": 6e-06, "average": 0.997813, "min": 0.994308}, "location": {"width": 143, "top": 654, "height": 128, "left": 911}, "words": "限公司"}, {"probability": {"variance": 0.000795, "average": 0.985187, "min": 0.895624}, "location": {"width": 280, "top": 756, "height": 43, "left": 767}, "words": "本品的剂量限制性毒性。尚"}, {"probability": {"variance": 0.004702, "average": 0.978422, "min": 0.664856}, "location": {"width": 911, "top": 779, "height": 69, "left": 217}, "words": "未建立本品的最大耐受剂量以16mg5g)每周两次皮下注射给药后"}, {"probability": {"variance": 0.024444, "average": 0.927727, "min": 0.367913}, "location": {"width": 877, "top": 818, "height": 89, "left": 217}, "words": "观测到类风湿关节炎患者的最大静脉负荷剂量为32mgm2一位类风湿大"}, {"probability": {"variance": 0.002113, "average": 0.985181, "min": 0.750812}, "location": {"width": 825, "top": 876, "height": 68, "left": 215}, "words": "患者错误的连续3周每周2次身行皮再注射62mg本品后未出现不良反应。目前"}, {"probability": {"variance": 1e-06, "average": 0.999538, "min": 0.997366}, "location": {"width": 245, "top": 927, "height": 39, "left": 214}, "words": "尚未发现本品的解毒剂"}, {"probability": {"variance": 0.000247, "average": 0.989838, "min": 0.955855}, "location": {"width": 135, "top": 975, "height": 35, "left": 218}, "words": "【临床试验】"}, {"probability": {"variance": 0.000241, "average": 0.996046, "min": 0.909899}, "location": {"width": 778, "top": 1021, "height": 65, "left": 255}, "words": "1、注射用依那西在国内外进行了成年类风湿关节炎患者和成年强直性脊"}, {"probability": {"variance": 0.00013, "average": 0.996574, "min": 0.932178}, "location": {"width": 827, "top": 1064, "height": 72, "left": 207}, "words": "柱炎患者的随机对照临床试验,其疗效得到确证。本品安佰诺在国内开展了相应"}, {"probability": {"variance": 0.002163, "average": 0.986642, "min": 0.800838}, "location": {"width": 411, "top": 1113, "height": 53, "left": 203}, "words": "的临床研究,疗效与国外同类产品类似"}, {"probability": {"variance": 5e-06, "average": 0.998423, "min": 0.990496}, "location": {"width": 776, "top": 1166, "height": 61, "left": 251}, "words": "2、在一项180例18岁及18岁以上成人中度及重度斑块状银屑病患者参加"}, {"probability": {"variance": 4e-06, "average": 0.998687, "min": 0.992134}, "location": {"width": 828, "top": 1213, "height": 61, "left": 201}, "words": "的多中心、随机、双盲、平行、阳性对照治疗(国内已上市同类药物)的临床试"}, {"probability": {"variance": 5e-06, "average": 0.998503, "min": 0.98978}, "location": {"width": 828, "top": 1261, "height": 61, "left": 199}, "words": "验中,试验组接受本品25mg,每周2次,连续12周皮下注射治疗,对照组接受"}, {"probability": {"variance": 0.000906, "average": 0.987001, "min": 0.868949}, "location": {"width": 816, "top": 1306, "height": 65, "left": 196}, "words": "同类阳性对照药相同剂量和给药方案治疗。疗效评价指标包括PASI50、PASI75"}, {"probability": {"variance": 0.000233, "average": 0.989922, "min": 0.924049}, "location": {"width": 430, "top": 1356, "height": 46, "left": 194}, "words": "PASI90、DLQI、PGA、VAS及SF-36等"}, {"probability": {"variance": 0.000382, "average": 0.99055, "min": 0.904218}, "location": {"width": 741, "top": 1404, "height": 60, "left": 243}, "words": "结果显示,FAS集下,治疗12周后试验组和对照组的PASI50、PASI75"}, {"probability": {"variance": 0.006047, "average": 0.97677, "min": 0.529287}, "location": {"width": 823, "top": 1452, "height": 61, "left": 190}, "words": "PASI90的应答率分别为75.6%和82.2%,51.5%和50%,30%和16.7%,两组间"}, {"probability": {"variance": 0.002139, "average": 0.979589, "min": 0.744643}, "location": {"width": 828, "top": 1498, "height": 64, "left": 187}, "words": "在PASI50应答率、PASI75应答率方面无显著性差异(p>0.05),在PASI90应"}], "language": 3}